BONS Stock Overview
A clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bonus BioGroup Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.12 |
| 52 Week High | ₪0.32 |
| 52 Week Low | ₪0.11 |
| Beta | 1.04 |
| 11 Month Change | -3.28% |
| 3 Month Change | -16.31% |
| 1 Year Change | -20.27% |
| 33 Year Change | -90.93% |
| 5 Year Change | -72.10% |
| Change since IPO | -50.83% |
Recent News & Updates
We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate
Apr 01
Will Bonus BioGroup (TLV:BONS) Spend Its Cash Wisely?
Dec 11We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate
Jun 14Recent updates
We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate
Apr 01Will Bonus BioGroup (TLV:BONS) Spend Its Cash Wisely?
Dec 11We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate
Jun 14Is Bonus BioGroup (TLV:BONS) In A Good Position To Deliver On Growth Plans?
Dec 13Companies Like Bonus BioGroup (TLV:BONS) Are In A Position To Invest In Growth
Jun 26Here's Why We're Not Too Worried About Bonus BioGroup's (TLV:BONS) Cash Burn Situation
Jan 28Here's Why We're Not Too Worried About Bonus BioGroup's (TLV:BONS) Cash Burn Situation
Sep 15Here's What Bonus BioGroup Ltd.'s (TLV:BONS) Shareholder Ownership Structure Looks Like
Mar 05What Kind Of Investors Own Most Of Bonus BioGroup Ltd. (TLV:BONS)?
Nov 19Shareholder Returns
| BONS | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 0.9% | -1.1% | 1.9% |
| 1Y | -20.3% | -7.3% | 26.9% |
Return vs Industry: BONS underperformed the IL Biotechs industry which returned -7.1% over the past year.
Return vs Market: BONS underperformed the IL Market which returned 28% over the past year.
Price Volatility
| BONS volatility | |
|---|---|
| BONS Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in IL Market | 7.4% |
| 10% least volatile stocks in IL Market | 2.8% |
Stable Share Price: BONS has not had significant price volatility in the past 3 months compared to the IL market.
Volatility Over Time: BONS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 58 | Shai Meretzki | bonus-bio.com |
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company’s products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts.
Bonus BioGroup Ltd. Fundamentals Summary
| BONS fundamental statistics | |
|---|---|
| Market cap | ₪137.82m |
| Earnings (TTM) | -₪29.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs BONS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BONS income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪29.19m |
| Earnings | -₪29.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BONS perform over the long term?
See historical performance and comparison